" class="no-js "lang="en-US"> Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma - Medtech Alert
Friday, February 03, 2023

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin’s Lymphoma

Accord Healthcare, a leading generic pharmaceutical company, has added Bendamustine Lyo Injection to its line of chemotherapy drugs to treat Leukemia and Non-Hodgkin’s Lymphoma. Accord’s product is AP rated to Teva’s Treanda® and is being offered in both 25-mg and 100-mg vials.

Bendamustine Lyo. Injection is in a class of medications called alkylating agents1. It works by killing existing cancer cells and limiting the growth of new cancer cells. Bendamustine is indicated for the treatment of adults with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or rituximab containing regimen.

“Adding Bendamustine Lyo. Injection to our line of available chemotherapy drugs is an important step in continuing to make oncology therapies more accessible to those who need them,” said Accord Healthcare President Jeff Hampton. “The availability of generics expands medication options for patients. When pharmacists have access to additional manufacturers, they are able to offer needed oncology products at a lower cost.”

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more